The use of in vitro cytokine-activated NK cells in combination with cetuximab, the monoclonal antibody (mAb) against epidermal growth factor receptor (EGFR), showed benefits, resulting in a higher ADCC response against human ICC cells [168]. This evidence concerns the gene EGFR and intrahepatic cholangiocarcinoma.